180 related articles for article (PubMed ID: 35466584)
1. Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non-small-cell lung cancer.
Zhang W; Han W; Yu B; Zhao X; Lu G; Wu W; Zhang Y
Thorac Cancer; 2022 Jun; 13(11):1642-1650. PubMed ID: 35466584
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Chen M; Xu Y; Zhao J; Zhong W; Zhang L; Bi Y; Wang M
EBioMedicine; 2019 Apr; 42():304-310. PubMed ID: 30878600
[TBL] [Abstract][Full Text] [Related]
3. [The expression of programmed death receptor 1 in non-small cell lung cancer and its clinicopathological features and prognosis showed a connection with epidermal growth factor receptor gene mutations].
Yin H; Liao CG; Wang YQ; Li Z; Fan LL; Qian ML; Lu N
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):419-423. PubMed ID: 28635230
[No Abstract] [Full Text] [Related]
4. Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Ito H; Isaka T; Imai K; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Tsuboi M; Nakayama H; Masuda M
BMC Cancer; 2014 Aug; 14():610. PubMed ID: 25152277
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
6. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
Wang H; Ou Q; Li D; Qin T; Bao H; Hou X; Wang K; Wang F; Deng Q; Liang J; Zheng W; Wu X; Wang X; Shao YW; Mou Y; Chen L
Cancer; 2019 Oct; 125(20):3535-3544. PubMed ID: 31287555
[TBL] [Abstract][Full Text] [Related]
7. Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases.
Xu Y; Huang Z; Yu X; Chen K; Fan Y
Mol Brain; 2021 Dec; 14(1):176. PubMed ID: 34952628
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity and Clinical Effect of Epidermal Growth Factor Receptor in Primary Lung and Brain Metastases of Nonsmall Cell Lung Cancer.
Xu S; Zhu J; Zhong D; Wang W; Wen Y; Zhang L; Jiang T
J Surg Res; 2023 Mar; 283():674-682. PubMed ID: 36459860
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer.
Wang S; Wang Z
Clin Oncol (R Coll Radiol); 2015 Jan; 27(1):30-9. PubMed ID: 25445553
[TBL] [Abstract][Full Text] [Related]
10. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
[TBL] [Abstract][Full Text] [Related]
11. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
12. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.
Gow CH; Chang YL; Hsu YC; Tsai MF; Wu CT; Yu CJ; Yang CH; Lee YC; Yang PC; Shih JY
Ann Oncol; 2009 Apr; 20(4):696-702. PubMed ID: 19088172
[TBL] [Abstract][Full Text] [Related]
13. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
[TBL] [Abstract][Full Text] [Related]
14. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
Lim SM; Kim HR; Cho EK; Min YJ; Ahn JS; Ahn MJ; Park K; Cho BC; Lee JH; Jeong HC; Kim EK; Kim JH
Oncotarget; 2016 Jun; 7(24):36311-36320. PubMed ID: 27121209
[TBL] [Abstract][Full Text] [Related]
15. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey.
Unal OU; Oztop I; Calibasi G; Baskin Y; Koca D; Demir N; Akman T; Ellidokuz H; Yilmaz AU
Asian Pac J Cancer Prev; 2013; 14(6):3705-9. PubMed ID: 23886169
[TBL] [Abstract][Full Text] [Related]
16. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
[TBL] [Abstract][Full Text] [Related]
17. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?
Mansuet-Lupo A; Zouiti F; Alifano M; Tallet A; Charpentier MC; Ducruit V; Devez F; Lemaitre F; Laurent-Puig P; Damotte D; Blons H
J Transl Med; 2014 May; 12():131. PubMed ID: 24885034
[TBL] [Abstract][Full Text] [Related]
19. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
20. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
